Environmentally persistent free radicals in PM2.5 from a typical Chinese industrial city during COVID-19 lockdown: The unexpected contamination level variation

• Authors : Wang, Lingyun ^{1, 2, #}; Zhao, Wuduo ^{1, 2, #}; Luo, Peiru ^{1, 2}

• Source: In Journal of Environmental Sciences January 2024 135:424-432

Record details

Impact of short-term ambient air pollution exposure on the risk of severe COVID-19

• Authors : Feng, Baihuan ^{1, 2, 3, #}; Lian, Jiangshan ^{4, #}; Yu, Fei ^{1, 2, 3}

• Source: In Journal of Environmental Sciences January 2024 135:610-618

Record details

Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape.

• Authors : Das R; Infectious Diseases, Moderna, Inc., Cambridge, MA, USA.; Hyer RN

• Source: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2023 Dec 31; Vol. 19 (1), pp. 2153532. Date of Electronic Publication: 2023 Jan 11.Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Willingness of college students to receive COVID-19 heterologous vaccination in Taizhou, China.

• Authors : Shao H; Department of Infectious Diseases, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang, China.; Lin XQ

• Source: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2023 Dec 31; Vol. 19 (1), pp. 2158012. Date of Electronic Publication: 2023 Jan 06.Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Rethinking the frontiers of vaccine acceptance: Impact of visual messages in promoting the actual intake of COVID-19 vaccines among vulnerable populations.

• Authors : Agujiobi-Odoh N; Department of Fine and Applied Arts, University of Nigeria, Nsukka, Nigeria.; Joseph IV

• Source: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2023 Dec 31; Vol. 19 (1), pp. 2163811. Date of Electronic Publication: 2023 Jan 10.Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variants during two outbreaks from March to May 2022 in Quzhou, China.

• Authors : Yin Z; Department of Immunity, Quzhou Center for Disease Control and Prevention, Quzhou, Zhejiang Province, China.; School of Public Health, Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China.

• Source: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2023 Dec 31; Vol. 19 (1), pp. 2163813. Date of Electronic Publication: 2023 Jan 27.Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Predicting COVID-19 vaccination uptake in Armenia using the Health Belief Model: Results from a nationwide survey.

• Authors : Harutyunyan T; Turpanjian College of Health Sciences, American University of Armenia, Yerevan, Armenia.; Sargsyan Z

• Source: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2023 Dec 31; Vol. 19 (1), pp. 2165383. Date of Electronic Publication: 2023 Jan 23.Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Progression of hemolysis in a patient with hereditary spherocytosis after the second dose of COVID-19 mRNA vaccine.

• Authors : Nomura J; Department of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai-shi, Japan.; Seki M

• Source: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2023 Dec 31; Vol. 19 (1), pp. 2165381. Date of Electronic Publication: 2023 Jan 10.Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines.

• Authors : Kyaw MH; Vaccine Medical Affairs, Emerging Markets, Pfizer Inc, Gaithersburg, MD, USA.; Spinardi J

• Source: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2023 Dec 31; Vol. 19 (1), pp. 2165856. Date of Electronic Publication: 2023 Feb 01.Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

COVID-19 vaccination up-take in three districts of Nepal.

• Authors : Pokhrel TN; Ministry of Health and Population, Kathmandu, Nepal.; Karki K

• Source: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2023 Dec 31; Vol. 19 (1), pp. 2166321. Date of Electronic Publication: 2023 Jan 24.Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details